Putting NAD+ into a vein leaves questions open
An IV delivers a substance into a vein. Showing that it helps someone is a separate job.
Does direct delivery mean direct benefit?
IV means intravenous: into a vein. An NAD+ infusion gives NAD+ itself. Much of the controlled human research instead tests swallowed precursors, ingredients the body uses to make NAD+.
It's easy to imagine an infusion as a shortcut to the same result. But changing the ingredient and the route changes the question. An oral study can't establish the benefits of an infusion just because both involve NAD+.
There's a useful clue in a laboratory experiment with cultured human skin cells. NAD was broken down outside the cells, which then took up a breakdown product called adenosine. Those were cells in a laboratory, so the finding doesn't show what an infusion does throughout a person.
It does help frame the question: where does the supplied substance go, and what does it do there? Reaching the bloodstream is one step. A useful effect in the body needs evidence too.
What has an infusion study measured?
A small NAD+ infusion pilot measured changes in blood and urine. Researchers were following how the body handled the infusion. That is useful work, but it didn't establish lasting improvements in energy, thinking or lifespan.
Those benefits need studies designed to measure them. A change in blood or urine can help explain where a substance went. It can't tell us, by itself, whether someone's daily life improved.
Even the better-studied oral precursors have limited evidence of health benefits. An infusion doesn't inherit their results. If a claim points to an oral study, the question about IV benefit is still waiting for its own answer.
What belongs in the conversation?
Compounded NAD+ is not FDA-approved. FDA explains that compounded medicines don't go through its approval review. A provider's prescription doesn't change that status.
Reported problems with fast NAD+ infusions into a vein include flushing (warm, red skin), nausea and chest or belly discomfort. Preparation quality matters too: compounded injections can carry contamination risks. The safety page explains why those concerns need separate attention.
Questions for a prescriber can stay plain: what exactly is proposed, and which research matches it? What risks matter for this person, and who handles concerns afterwards?
This guide can't choose an amount or an infusion length. It gives no recommendation to begin, stop or change treatment. An honest conversation can include an unknown without rushing past it.
Into the bloodstream isn't the same as a proven benefit.